Article
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
Neutral
0.0
−100 Bearish
0
+100 Bullish
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
CNBC Top Stories
Published
Jul 16, 2026 · 10:48 am
Article ID
rcgc2h0
Original URL
Open source
Sentiment Signal
Neutral
0.0
−100Neutral+100
More Like This